Prevention of drug resistance by combined drug treatment of tuberculosis

Handbook of Experimental Pharmacology

Volumn 211, Issue , 2012, Pages 87-98

  Mitchison, Denis A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Chromosomal mutation; Drug activity; Drug resistance; Mycobacterium tuberculosis; Post antibiotic effect

Indexed keywords

AMINOSALICYLIC ACID; BEDAQUILINE; CLOFAZIMINE; DAPSONE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CHROMOSOME; BACTERIAL STRAIN; BACTERIUM CULTURE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; GENE MUTATION; HUMAN; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMID; PRIORITY JOURNAL; TREATMENT DURATION; TUBERCULOSIS; DRUG COMBINATION; GENETICS; MUTATION; REVIEW;

DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MUTATION; TUBERCULOSIS;

EID: 84870226660     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-28951-4_6     Document Type: Article

References (57)

1. Andrews RH, Devadatta S, Fox W, Radhakrishna S, Ramakrishnan CV, Velu S (1960) Prevalence of tuberculosis among close family contacts of tuberculous patients in South India, and influence of segregation of the patient on the early attack rate. Bull World Health Organ 23:463-510
2. Awaness AM, Mitchison DA (1973) Cumulative effects of pulsed exposures of Mycobacterium tuberculosis to isoniazid. Tubercle 54:153-158
3. Cohen T, Wilson D, Wallengren K, Samuel EY, Murray M (2011) Mixed-strain Mycobacterium tuberculosis infections among patients dying in a hospital in KwaZulu-Natal, South Africa. J Clin Microbiol 49:385-388
4. Crofton J (1958) Sputum conversion and the metabolism of isoniazid. Am Rev Tuberc 77:869-871
5. Dawson JJY, Devadatta S, Fox W, Radhakrishna S, Ramakrishnan CV, Somasundaram PR, Stott H, Tripathy SP, Velu S (1966) A 5-year study of patients with pulmonary tuberculosis in a concurrent comparison of home and sanatorium treatment for one year with isoniazid plus PAS. Bull World Health Organ 34:533-551
6. Dickinson JM, Mitchison DA (1966) In vitro studies on the choice of drugs for intermittent chemotherapy of tuberculosis. Tubercle 47:370-380
7. Dickinson JM, Mitchison DA (1970) Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle 51:82-94
8. Donald PR, Sirgel FA, Botha FJ, Seifart HI, Parkin DP, Vandenplas ML, Van de Wal BW, Maritz JS, Mitchison DA (1997) The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 156:895-900 (Pubitemid 27396432)
9. Donald PR, Sirgel FA, Venter A, Smit E, Parkin DP, Van de Wal BW, Dore CJ, Mitchison DA (2002) The early bactericidal activity of streptomycin. Int J Tuberc Lung Dis 6:693-698 (Pubitemid 34832149)
10. East African/British Medical Research Council (1972) Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 299: 1079-1085
11. East and Central African/British Medical Research Council (fifth Collaborative Study) (1986) Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tubercle 67:5-15
12. Elliott AM, Berning SE, Iseman MD, Peloquin CA (1995) Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tuber Lung Dis 76:463-467
13. Fox W (1953) The medical research council trials of isoniazid. Recent results of combined chemotherapy. Bull Int Union Tuberc Lung Dis 23:292-307
14. Fox W, Ellard GA, Mitchison DA (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3:S231-S279 (Pubitemid 29481843)
15. Fox W, Sutherland I (1956) A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid, and streptomycin plus para-aminosalicylic acid, in pulmonary tuberculosis. Q J Med 25:221-243
16. Fox W, Sutherland I, Daniels M (1954) A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis. Q J Med 23:347-366
17. Fox W, Wiener A, Mitchison DA, Selkon JB, Sutherland I (1957) The prevalence of drug-resistant tubercle bacilli in untreated patients with pulmonary tuberculosis: A national survey, 1955-56. Tubercle 38:71-84
18. Ginsburg AS, Lee J, Woolwine SC, Grosset JH, Hamzeh FM, Bishai WR (2005) Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system. Antimicrob Agents Chemother 49:853-856 (Pubitemid 40175717)
19. Gumbo T, Dona CS, Meek C, Leff R (2009) Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 53:3197-3204
20. Hong Kong Tuberculosis Treatment Services and East African/British Medical Research Councils (1976) First-line chemotherapy in the retreatment of bacteriological relapses of pulmonary tuberculosis following a short-course regimen. Lancet 1:162-163
21. Hong Kong Chest Service/British Medical Research Council (1991) Controlled trial of 2, 4 & 6 months of pyrazinamide in 6-month, 3 x weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide. Am Rev Respir Dis 143:700-706
22. Hu Y, Mangan JA, Dhillon J, Sole KM, Mitchison DA, Pd B, Coates ARM (2000) Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol 182:6358-6365
23. Hu Y, Coates ARM, Mitchison DA (2003) Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 47:653-657 (Pubitemid 36158096)
24. Huang HY, Tsai YS, Lee JJ, Chiang MC, Chen YH, Chiang CY, Lin NT, Tsai PJ (2010) Mixed infection with Beijing and non-Beijing strains and drug resistance pattern of Mycobacterium tuberculosis. J Clin Microbiol 48:4474-4480
25. Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N (2007) Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 51:1011-1015 (Pubitemid 46355288)
26. International Union against Tuberculosis (1964) An international investigation of the efficacy of chemotherapy in previously untreated patients with pulmonary tuberculosis. Bull Int Union Tuberc 34:80-191
27. Ji BH (1985) Drug resistance in leprosy - a review. Lepr Rev 56:265-278
28. Jindani A, Aber VR, Edwards EA, Mitchison DA (1980) The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 121:939-949 (Pubitemid 10118376)
29. Jindani A, Doré CJ, Mitchison DA (2003) The bactericidal and sterilising activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 167:1348-1354 (Pubitemid 36609718)
30. Jindani A, Griffin GE (2010) Challenges to the development of new drugs and regimens for tuberculosis. Tuberculosis (Edinb) 90:168-170
31. Lehmann J (1946) Para-aminosalicylic acid in the treatment of tuberculosis. Lancet 5(1):15
32. Mallard K, McNerney R, Crampin AC, Houben R, Ndlovu R, Munthali L, Warren RM, French N, Glynn JR (2010) Molecular detection of mixed infections of Mycobacterium tuberculosis strains in sputum samples from patients in Karonga District, Malawi. J Clin Microbiol 48:4512-4518
33. Matsuoka M (2010) Drug resistance in leprosy. Jpn J Infect Dis 63:1-7
34. Medical Research Council (1948) Streptomycin treatment of pulmonary tuberculosis. Br Med J 2:769-782
35. Medical Research Council (1950) Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid. Br Med J 2:1073-1085
36. Medical Research Council (1953a) Isoniazid in the treatment of pulmonary tuberculosis. Second report. Br Med J 1:521-536
37. Medical Research Council (1953b) Emergence of bacterial resistance in pulmonary tuberculosis under treatment with isoniazid, streptomycin plus PAS, and streptomycin plus isoniazid. Lancet 262:217-223
38. Mitchison DA (1954) Problems of drug resistance. Br Med Bull 69:640-641
39. Mitchison DA (1979) Basic mechanisms of chemotherapy. Chest 76S:771-781S
40. Mitchison DA (1980) Treatment of tuberculosis. J R Coll Physicians Lond 14:91-99
41. Mitchison DA (1998) How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 2:10-15 (Pubitemid 28108937)
42. Mitchison DA, Coates ARM (2004) Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs. Curr Pharm Des 10:3285-3295 (Pubitemid 39276616)
43. Mitchison DA, Dickinson JM (1971) Laboratory aspects of intermittent drug therapy. Postgrad Med J 47:737-741
44. Mitchison DA, Selkon JB (1957) Bacteriological aspects of a survey of the incidence of drug-resistant tubercle bacilli among untreated patients. Tubercle 38:85-98
45. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer M (2010) Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am J Respir Crit Care Med 181:174-180
46. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA, the Gatifloxacin for TB (OFLOTUB) study team (2008) A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12:128-138 (Pubitemid 351212403)
47. Shamputa IC, Jugheli L, Sadradze N, Willery E, Portaels F, Supply P, Rigouts L (2006) Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respir Res 7:99
48. Sirgel FA, Botha FJH, Parkin DP, Van de Wal BW, Donald PR, Clark PK, Mitchison DA (1993) The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts. A new method of drug assessment. J Antimicrob Chemother 32:867-875 (Pubitemid 24026587)
49. Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, Roscigno G, Norman J, McIllernon H, Mitchison DA, and the Rifapentine EBA Collaborative Study Group (2005) The early bactericidal activities of rifampicin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 172:128-135 (Pubitemid 40923325)
50. Sulochana S, Mitchison DA, Kubendiren G, Venkatesan P, Paramasivan CN (2009) Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis. J Chemother 21:127-134
51. Tuberculosis Chemotherapy Centre, Madras (1959) A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull World Health Organ 21:51-144
52. Vandamme AM, Van Vaerenbergh K, De Clercq E (1998) Anti-human immunodeficiency virus drug combination strategies. Antivir Chem Chemother 9:187-203 (Pubitemid 28273053)
53. Waters MF (1983) The treatment of leprosy. Tubercle 64:221-32 (Pubitemid 13042310)
54. WHO Study Group (1982) Chemotherapy of leprosy for control programs. WHO Tech rep Ser 675
55. WHO Expert Committee on Leprosy (1998) Seventh Report. World Health Organ Tech Rep Ser 874:1-43
56. World Health Organization Regional Office for South-East Asia New Delhi (2006) Global strategy for further reducing the leprosy burden and sustaining leprosy control activities 2006-2010. Operational guidelines. Lepr Rev 77:1-50
57. Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA, Nuermberger EL, Grosset JH (2011) Treatment of tuberculosis with rifamycin-containing regimens in immune deficient mice. Am J Respir Crit Care Med 183:1254-1261